FGF23 and diabetes mellitus: SGLT2 inhibitors are also thought to promote renal phosphate reabsorption, increase fibroblast growth factor 23 and PTH, and act by decreasing active vitamin D, causing calciuria [65]; however, the effects of diabetes medications on bone health need further study.